Literature DB >> 17505252

Chikungunya infection: an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases.

Fabrice Simon1, Philippe Parola, Marc Grandadam, Sabrina Fourcade, Manuela Oliver, Philippe Brouqui, Pierre Hance, Philippe Kraemer, Anzime Ali Mohamed, Xavier de Lamballerie, Rémi Charrel, Hugues Tolou.   

Abstract

A large chikungunya virus (CHIKV) outbreak emerged in 2005-2006 in the Indian Ocean islands, including Comoros, Mayotte, Mauritius, the Seychelles, and particularly in Reunion Island where 35% of 770,000 inhabitants were infected in 6 months. More recently, circulation of the virus has been documented in Madagascar and in India where CHIKV is spreading rapidly. CHIKV-infected visitors have returned home to nonendemic regions from these islands. We conducted a 14-month prospective observational study on the clinical aspects of CHIKV infection imported to Marseilles, France, in travelers returning from the Indian Ocean islands. A total of 47 patients have been diagnosed with imported CHIKV infection confirmed by serology, reverse transcription-polymerase chain reaction, and/or viral culture. At the early stage of the disease (within 10 days of the disease onset), fever was present in 45 of 47 patients. A rash was present in the first week in 25 cases. All patients suffered with arthritis. The most frequently affected joints were fingers, wrists, toes, and ankles. Eight patients were hospitalized during the acute stage, including 2 severe life-threatening cases. A total of 38 patients remained symptomatic after the tenth day with chronic peripheral rheumatism, characterized by severe joint pain and multiple tenosynovitis, with a dramatically limited ability to ambulate and carry out activities in daily life. Three patients were hospitalized at this stage for severe persistent handicap. Follow-up demonstrated slow improvement in joint pain and stiffness despite symptomatic treatment, mainly antiinflammatory and analgesic drugs. In the current series we describe 2 stages of the disease, an initial severe febrile and eruptive polyarthritis, followed by disabling peripheral rheumatism that can persist for months. We point out the possibility of transitory peripheral vascular disorders during the second stage and the occasional benefit of short-term corticosteroids. As CHIKV could spread throughout the world, all physicians should be prepared to encounter this arboviral infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17505252     DOI: 10.1097/MD/0b013e31806010a5

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  96 in total

Review 1.  Management of chikungunya arthritis.

Authors:  J Kennedy Amaral Pereira; Robert T Schoen
Journal:  Clin Rheumatol       Date:  2017-08-03       Impact factor: 2.980

2.  Chikungunya disease in nonhuman primates involves long-term viral persistence in macrophages.

Authors:  Karine Labadie; Thibaut Larcher; Christophe Joubert; Abdelkrim Mannioui; Benoit Delache; Patricia Brochard; Lydie Guigand; Laurence Dubreil; Pierre Lebon; Bernard Verrier; Xavier de Lamballerie; Andreas Suhrbier; Yan Cherel; Roger Le Grand; Pierre Roques
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

3.  A nonhuman primate model of chikungunya disease.

Authors:  Stephen Higgs; Sarah A Ziegler
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

Review 4.  Novel infectious agents causing uveitis.

Authors:  Moncef Khairallah; Soon Phaik Chee; Sivakumar R Rathinam; Sonia Attia; Venu Nadella
Journal:  Int Ophthalmol       Date:  2009-08-27       Impact factor: 2.031

Review 5.  Emerging viral infections of the central nervous system: part 2.

Authors:  Kenneth L Tyler
Journal:  Arch Neurol       Date:  2009-09

6.  How many patients with post-chikungunya chronic inflammatory rheumatism can we expect in the new endemic areas of Latin America?

Authors:  A J Rodriguez-Morales; J A Cardona-Ospina; W Villamil-Gómez; A E Paniz-Mondolfi
Journal:  Rheumatol Int       Date:  2015-06-05       Impact factor: 2.631

7.  Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation of the effects of polyanions.

Authors:  Ryan M Kramer; Yuhong Zeng; Neha Sahni; Lisa A Kueltzo; Richard M Schwartz; Indresh K Srivastava; Lindsey Crane; Sangeeta B Joshi; David B Volkin; C Russell Middaugh
Journal:  J Pharm Sci       Date:  2013-10-15       Impact factor: 3.534

8.  Chikungunya fever: focus on peripheral markers of pathogenesis.

Authors:  Pierre Roques; Gabriel Gras
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

9.  A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence.

Authors:  Thomas E Morrison; Lauren Oko; Stephanie A Montgomery; Alan C Whitmore; Alina R Lotstein; Bronwyn M Gunn; Susan A Elmore; Mark T Heise
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

10.  γδ T Cells Play a Protective Role in Chikungunya Virus-Induced Disease.

Authors:  Kristin M Long; Martin T Ferris; Alan C Whitmore; Stephanie A Montgomery; Lance R Thurlow; Charles E McGee; Carlos A Rodriguez; Jean K Lim; Mark T Heise
Journal:  J Virol       Date:  2015-10-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.